Asset Details
Do you wish to reserve the book?
‘Immune reset plus’: the case for combining immunotherapies to maintain self-tolerance in autoimmune diseases
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
‘Immune reset plus’: the case for combining immunotherapies to maintain self-tolerance in autoimmune diseases
Do you wish to request the book?
‘Immune reset plus’: the case for combining immunotherapies to maintain self-tolerance in autoimmune diseases
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
‘Immune reset plus’: the case for combining immunotherapies to maintain self-tolerance in autoimmune diseases
2025
Overview
[...]tumour treatment improves the symptoms of autoimmune disease by reducing the antigenic stimulus arising from the tumour. [...]clinical use of aHSCT for treatment of autoimmune diseases is only available in specialised clinics and does not have regulatory approval in most countries. PIPs preferentially bind to class II MHC molecules on ssDC since these cells do not load class II with peptide epitopes efficiently resulting in expression of unstable or peptide receptive class II MHC molecules at the cell surface (28). [...]peptide epitopes can be presented by artificial APCs prepared by coating nanoparticles with MHC class II molecules (37).
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
